TOTAL VOLUME:
$97.5b
24H VOL:
$266,367,375
24H TRANSACTIONS:
960,901,819
OPEN INTEREST:
$2,196,061,598
832,481
Markets across
15,126
events
MATCHED EVENTS:
961
PLATFORM COVERAGE:
5
Polymarket:
45%
VS.
Kalshi:
55%
Time left: 15d:05h:31m
$
$20
$50
$100
$500
This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.
This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.
Prediction market odds often diverge from traditional analyst forecasts because they incorporate real-time trading by informed participants with financial incentive to be accurate. While public health agencies and epidemiologists publish outbreak projections based on surveillance data, this market aggregates dispersed knowledge from traders monitoring case counts, transmission patterns, and policy responses. Markets tend to update faster than formal forecasts when new evidence surfaces. Comparing the two reveals whether the crowd is more or less optimistic than official guidance, offering a complementary lens on outbreak trajectory.
On Polymarket, this market is priced through an automated market maker that converts trader activity into real-time odds. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. When you buy shares predicting a higher case count, you push the price up; selling pushes it down. The current odds reflect the marginal trader's belief about outbreak severity by the deadline. Liquidity and trading volume influence how quickly prices adjust to new information, so periods of high activity often correlate with significant public health announcements or case count updates.
This market resolves around Jul 31, 2026, with the outcome confirmed once verified case counts are available from credible public sources. The specific threshold—whether cases reach the predicted level—will be assessed against official U.S. public health reporting at that time. Until resolution, the market remains open for trading, allowing participants to adjust positions as new epidemiological data becomes available. Final settlement depends on the accuracy of reported case totals as of the deadline.
Weekly case reports from the CDC and state health departments are primary catalysts, as rising or falling numbers directly inform outbreak trajectory. Identification of new contamination sources—such as produce recalls or food distribution patterns—can shift expectations sharply. Policy changes, including enhanced surveillance or public warnings, may influence transmission rates and trader positioning. Seasonal factors and travel patterns also matter; summer months historically see cyclosporiasis clusters. Any major shift in confirmed cases or epidemiological findings will likely trigger repricing as traders reassess the probability of reaching the threshold by July 31.
Follow the signals, not the noise
Get insights on market conviction, notable shifts, and what the data is quietly signaling.